

We’ve all been there
Hey there, it’s Vadim 👋
I want to level with you.
For most people, pitch decks are not what gets them out of bed in the morning.
When you pursued your PhD, when you spent those long hours at the bench, when you took time away from your family to fly to a conference and stand by a poster - I bet it wasn’t because you dreamed of one day producing the perfect collection of PowerPoint slides.
You were trying to solve an important problem.
So I understand the reaction I get most often from founders. When a founder reaches out to me for help raising their round, and I ask about their deck, what I often get back is a knowing shrug: it's good enough.
And here's the tough part: at first glance, it usually is.
There's a science slide. A product slide. A clinical development overview. A team slide. Even a clean Ask slide. All the pieces I usually talk about - they're there.
And yet something is just... off.
Investors feel it too. They can't always name it, and they rarely have time to explain it, but they feel it - and then the energy in the conversation quietly begins to shift.
Here's what I've come to believe, after sitting on both sides of these conversations.
Before you polish a single slide, you need to make sure the story underneath it can carry the weight.
And for most founders, that’s where the real work begins: building a fundable story.
A story that goes beyond conveying information and achieves what a good deck is meant to do: build enough trust and conviction that an investor leans in and wants to learn more about your company, rather than politely watching from the sidelines.
The challenge with “good enough” decks is that their biggest problems are rarely obvious at first glance.
They tend to show up in the spaces between the slides, where the logic weakens, the investor has to connect the dots, and conviction quietly begins to leak out - often without the founder ever finding out where.
This is exactly what I'll be working on this week with a select group of founders in the Bio Founder GPS Pitch Deck Intensive, which kicks off Tuesday. Enrollment closes Monday at 11:59 p.m. ET.
But for today, I want to help you begin identifying those gaps yourself.
🧭 HERE’S WHAT WE’LL COVER:
How investors build conviction
The ten places where that conviction most often begins to leak
A 20-minute audit you can use before sending your deck again
How to turn a complete deck into a story that creates action
And more!
All right - let's find those leaks 🪣
FRAMEWORK
The dangerous middle ground
The easiest decks to diagnose are the ones with obvious gaps.
They may be missing a key slide, bury the investor in raw data, leave the financing plan unclear, or raise major questions that the founder never addresses.
At the other end are the rare decks that make the company easy to understand, easy to remember, and easy to discuss inside the fund. They create enough trust, curiosity, and urgency that the next step feels natural.
The decks hardest to diagnose sit in the middle.
They contain all the expected sections. The science appears credible. The market looks attractive. The slides may even be professionally designed.
But the investor is still being asked to connect too many dots.

That middle is where Conviction Leaks live.
To understand where they appear, it helps to first understand what the investor is trying to piece together as they move through your deck.
How conviction actually builds
When an investor reads your deck, they’re trying to construct a chain of belief:
The problem matters → your approach can solve it → the evidence supports the approach → the opportunity can create meaningful value → your team can execute → this round reaches an important inflection point.
Every slide should strengthen one part of that argument and make the next step easier to accept.
A Conviction Leak appears when one of those links is missing, weak, or left implicit.
Your market slide may show a $20 billion opportunity without explaining where you can realistically enter. Your data may look encouraging without showing which key element has been de-risked.
This is not so much a gap in actual company building, as it is in storytelling. It means the investor has to work harder to understand why the company is strong.
Most Conviction Leaks tend to fall into one of three categories:
Gaps in the story
Gaps in the evidence
Gaps in the investor’s confidence that the team can execute and create value with the next round
Across those three areas, there are ten leaks I see again and again in otherwise promising biotech decks.
Let’s start with the story itself, because if the investor can’t clearly follow the argument, the rest of the deck has very little room to work.
STORY LEAKS
1. The problem is large, but your wedge is unclear
Almost every biotech deck begins with a large disease burden, an inadequate standard of care, and substantial unmet need.
Those facts establish that the problem matters. But they do little to position where your company can enter and create value.
For example, you may know the exact biological failure, patient subgroup, diagnostic delay, or workflow bottleneck your product addresses. But on your slides, the investor may only see a broad disease category and a very large market number.
Now, move from the macro problem to the specific failure point. Who is affected, what breaks today, and why have existing approaches failed to address it?
A focused wedge doesn’t diminish the potential of what you’re building - quite the contrary. It gives the investor a credible place to begin and a clearer way to understand how your company can establish early traction.
2. The science is clear, but the investment thesis is missing
Technical founders spend a great deal of time helping investors understand the mechanism, especially when the biology is novel.
The challenge is that understanding the science and understanding the investment are related, but very separate steps in the evaluation process.
For example, I recently reviewed a therapeutics deck where I was able to understand the pathway and intervention point, but still couldn’t tell why the approach could produce a meaningfully better drug than the competing programs.
That translation needs to appear in the deck. Does the science produce a better therapeutic index, open previously inaccessible biology, improve patient selection, or create a repeatable development engine?
Explain what the technology does, but then connect it to the product and business advantage it creates. The investor shouldn’t have to make that leap alone.
3. The first indication is compelling, but the selection logic is invisible
When investors ask, “Why did you choose this indication first?” they’re usually evaluating more than the disease opportunity.
They want to understand how you make strategic decisions.
Perhaps the indication offers the strongest biological fit, fastest route to proof of concept, clearest regulatory path, or most concentrated patient population. Whatever the answer, the choice should feel deliberate.
At early stages, you may not need a 12-factor matrix or discounted cash flow model.
One clear sentence may be enough. For example:
We selected this genetically defined solid-tumor indication because it combines strong mechanistic fit, a concentrated patient population, limited treatment options, and the potential to generate an interpretable clinical signal in a focused development program.
A sentence like this can signal that the team understands how biology, development, and financing fit together. It can also serve as a great first step to a more detailed conversation.
4. The deck shows competitors, but never makes the competitive argument
Competitive slides often contain logos, two-by-two matrices, or tables filled with green checkmarks.
The problem is that comparison alone does not establish differentiation.
The investor needs to understand what you are meaningfully better at, why that advantage matters, and how difficult it will be for others to reproduce.
Before designing the slide, complete this sentence:
The most important thing an investor should understand about our differentiation is ______.
Once that claim is clear, the rest of the slide can support it through data, product characteristics, workflow advantages, or IP.
Done right, it can allow you to show where you have an advantage that matters to patients, customers, partners, or the development path.
EVIDENCE LEAKS
5. The claims are stronger than the evidence presented
Biotech decks are full of phrases such as best-in-class, clinically validated, de-risked, and strong commercial demand.
Sometimes those claims are accurate. Other times, the evidence supports something narrower.
A pilot may demonstrate feasibility without establishing clinical validation. A KOL quote may confirm the importance of the problem without demonstrating that the product will be adopted. A pharma conversation may signal interest without proving willingness to partner.
Separate the claim, the evidence, and the conclusion.
For example:
In a blinded set of 84 patient samples, our assay distinguished cases from controls with 91% sensitivity and 88% specificity.
Then explain what the result supports:
These findings establish the feasibility of using the biomarker as the basis for a clinical diagnostic.
The second statement may sound more measured than “clinically validated,” but it’s also more credible.
That credibility and transparency is what builds conviction.
6. The data are positive, but the investor can’t tell what changed
This is probably the most common comment I leave on data slides.
The result looks encouraging, but the deck never explains what uncertainty existed before the experiment or what uncertainty was reduced afterward.
A molecule hit the target. A biomarker separated two groups. A mouse study showed efficacy. What does that result now allow the company to do?
Give the experiment a clear job. For example:
Question: Can the lead candidate suppress the disease-driving pathway at clinically relevant exposure?
Then show the data and explain the implication:
The results support advancement into IND-enabling studies and reduce the core pharmacology risk that previously limited the program.
The figure shows what happened but your interpretation tells the investor why it matters and how the development plan has changed.
7. External validation is impressive, but its meaning is unclear
Grants, accelerators, pharma discussions, hospital collaborations, and pilot customers can all strengthen the story.
But they don’t all validate the same thing.
A grant may validate scientific merit. A hospital partnership may reduce sample-access risk. A paid pilot may demonstrate willingness to engage, while a commercial contract starts to demonstrate willingness to pay.
The investor shouldn’t have to guess which interpretation applies.
Instead of saying that you’re “working with three leading hospitals,” explain that those hospitals are providing retrospective samples and workflow input, reducing data-access risk ahead of prospective validation.
The logos can stay, just make sure the meaning behind it is also visible.
EXECUTION AND FUNDABILITY LEAKS
8. The team slide shows impressive people without showing execution fit
Advanced degrees, publications, prior employers, and successful exits are all useful signals.
But investors are still trying to answer a more immediate question: can this team deliver the next stage of the plan?
Connect each person to a milestone or risk. For example: the scientific founder led the work through in vivo validation. The development lead advanced two prior programs into the clinic. The clinical advisor runs a major referral center for the target population.
This framing also helps you show the gaps honestly.
A thoughtful hiring plan often creates more confidence than pretending the company already possesses every capability it will need. Investors know that early-stage teams are incomplete. They want to see that you know what needs to be added and when.
9. The ask explains how the money will be spent without explaining what it will prove
Many ask slides say something like:
Raising $4 million for 24 months of runway.
Then comes a pie chart showing spending across R&D, personnel, clinical work, regulatory activities, and G&A.
The budget may be accurate, but it doesn’t explain what becomes true at the end of the round.
A stronger version might read:
This $4 million seed round funds prospective validation in 150 patients, establishing the performance package required for FDA engagement and a Series A financing.
The budget can then show how you reach that point.
Founders naturally think in terms of runway, but investors think in terms of value creation. Connect the amount raised to a specific milestone, and that milestone to a more valuable and financeable company.
10. The deck never fully answers why the opportunity matters now
The final leak often runs through the entire presentation rather than appearing on one slide.
The disease may have existed for decades, the biology may have been studied for years, and competitors may already be active in the space.
Why can this company be built today?
The answer may involve a new dataset, regulatory shift, falling technology cost, validated therapeutic class, or scientific insight that only recently became actionable.
“Why now?” should appear throughout the deck. The science may show the breakthrough, the market may show the opening, and the development plan may explain why the next 18 months matter.
A company can have excellent science and still feel easy to postpone. Once the investor decides to revisit the opportunity after the next experiment, the round becomes much harder to close.
YOUR 20 MINUTE CONVICTION AUDIT
Before sending your deck again, open it in presentation mode and review it one slide at a time.
For each slide, answer five questions:
1. What conclusion should the investor reach?
“Market” is a topic. “We can build a venture-scale company by entering through a concentrated $1.2 billion beachhead” is a story.
2. What evidence supports that conclusion?
Look for data, benchmarks, customer behavior, published research, development precedent, or comparable transactions.
3. What does the investor still have to assume?
Perhaps they must assume that the indication is attractive, the biomarker will translate, or the milestone will support the next financing.
4. Is that missing logic resolved elsewhere?
Sometimes the answer exists six slides later. Move critical logic closer to the claim it supports.
5. Could the title state the conclusion more clearly?
“Competitive Landscape” labels the slide. “Our approach detects disease earlier than existing methods” advances the argument.
Then ask one final question about the full deck:
Where am I asking the investor to connect dots that I should connect for them?
Start with the three places where the missing logic creates the greatest uncertainty.
Fixing those may do a lot more for the story than adding new slides or cramming more text into existing ones.
THAT’S A WRAP!
Here’s what I’d like you to leave with today:
A deck can include every expected slide and still fail to move an investor forward.
The problem is often not the formatting, not fonts, and not even the amount of information packed into the slides. It’s the logic and the heavy lifting that the investor is still being asked to supply.
So, before you add another slide, redesign the market page, or spend three hours moving boxes around in PowerPoint, I’d suggest doing three things:
1. Name the conclusion behind every slide
Do not write “Science,” “Market,” or “Team.” Write the specific idea you want the investor to believe after seeing that slide.
2. Find the three biggest leaps in the story
Where does the investor have to connect the mechanism to the product advantage, the evidence to the risk retired, or the financing to the value created?
3. Patch those leaks before adding anything new
A clearer title, one sentence of interpretation, or a better transition may do more for the story than another page of information.
This is also exactly why I built the Bio Founder GPS Pitch Deck Intensive as a live, feedback-driven program rather than a collection of videos.
You can read all ten Conviction Leaks above and understand them perfectly. The harder part is recognizing where they appear in your own story.
You already know why the first indication was selected. You know which experiment changed your thinking. You know how the technology leads to the product, and what the next round is supposed to unlock.
Because you know all of that, your mind fills in the gaps automatically.
The investor’s mind will not.
Starting this Tuesday, I’ll be working with a select group of science-driven founders over six weeks to build the investor story their science deserves.
Across 12 live sessions, we’ll work through:
Your core investment thesis and strategic wedge
The story behind the science and evidence
Your indication, market, and competitive positioning
The milestones, financing ask, and value inflection point
The complete narrative and flow of the deck
You’ll also receive direct feedback as you revise, lifetime access to the recordings and materials, and ongoing support inside the cohort community.
For this founding cohort, enrollment also includes the Fundraising Intensive that will follow soon after, where we’ll move from building the story to identifying the right investors, structuring your outreach, and running the raise.
The Pitch Deck Intensive helps you build conviction.
The Fundraising Intensive helps you turn that conviction into a process.
Enrollment closes tomorrow, Monday at 11:59 p.m. ET, and this is the only cohort where both programs will be included together in this form.
If you’re interested but still wondering whether the Intensive is the right fit for your company and stage, just reply to this email. I’m happy to jump on a quick call, hear where you are in the process, and help you think it through.
Whether or not you join us, take 20 minutes this week and find the three biggest Conviction Leaks in your deck.
You may discover that the next version does not need more information.
It simply needs to make the argument easier to believe.
Until next week,
Vadim
PS: If you run the audit and find a slide you’re unsure about, reply and tell me which one. I’d be curious to hear where these leaks are showing up most often.